 |
|
|
| |
3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Athens, Greece - October 2001 |
| |
| |
- Nephrotoxicity in patients randomized to Indinavir 800 mg 3x/week or indinavir/ritonavir 800/100 twice per day -Jan 04, 2002
- Fat Loss: efavirenz + AZT/3TC vs indinavir AZT/3TC in study 006 - Dec 17, 2001
- LIPID ABNORMALITIES AND CARDIOVASCULAR RISK Written for NATAP by Michael Dube, MD, University of Indiana and the ACTG - Nov 2, 2001
- Abnormalities of Glucose Metabolism, Including Insulin Resistance Michael Dube, MD,
University of Indiana and ACTG researcher - Nov 2, 2001
- Risk for Increased Heart Disease in 45-Year Old Women with HIV and Lipodystrophy - Nov 2, 2001
- Report on Possible Therapy for Lipodystrophy Written for NATAP by Cecilia Shikuma, MD, the University of Hawaii and the
ACTG - Oct 31, 2001
- Report on Lactic Acidosis and other Mitochondrial Toxicity Issues Written for NATAP by Cecilia Shikuma, MD, the University of Hawaii and the
ACTG - Oct 31, 2001
- High prevalence of Thyroid Abnormalities in the era of HAART - Oct 28, 2001
- Nevaripine: lipids and heart disease; hepatotoxicity and a role for therapeutic drug monitoring - Oct 26, 2001
- Mitochondrial Toxicity and Lipodystrophy - Oct 26, 2001
- Abacavir: Fat Redistribution, and Changes in Cholesterol & Triglycerides - Oct 26, 2001
- Bulletted Highlights From Lipodystrophy Workshop - Oct 25, 2001
- Amprenavir and Effects on Metabolics & Lipoatrophy - Oct 24, 2001
- Lipodystrophy, Protease Inhibitors, and Insulin Resistance - Oct 23, 2001
- Pre-Conference Overview - Oct 22, 2001
|
|
| |
|
|
|
|
|
